EMA begins review of Novavax's Covid-19 vaccine

On Wednesday, the vaccine developer Novavax received confirmation that the EU health authorities have started processing the company's marketing application.


On Wednesday, the US-based biotech company and vaccine developer Novavax was notified by the European Medicines Agency (EMA) that work has begun on the assessment of the company's filing for conditional marketing authorization of its Covid-19 vaccine, Nuvaxovid, it reports in a press release.

"The assessment will proceed under an accelerated timeline, and an opinion on the marketing authorization could be issued within weeks if the data submitted are sufficiently robust and complete to show the efficacy, safety and quality of the vaccine," the EMA writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs